Publication for COL1A1 and COL11A1

Species	Symbol	Function*	Entrez Gene ID*	Other ID	Gene coexpression	CoexViewer
hsa	COL1A1	collagen type I alpha 1 chain	1277			[link]
hsa	COL11A1	collagen type XI alpha 1 chain	1301

Pubmed ID	Priority	Text
31598423	1.00	COL1A1, COL10A1 and COL11A1 were notably overexpressed in ESCC compared to normal tissues.
	0.96	COL1A1, COL10A1 and COL11A1 were particularly up-regulated in ESCC tissues compared to normal controls, while COL4A4, COL6A5 and COL14A1 were notably down-regulated.
	0.96	COL1A1, COL10A1 and COL11A1 was particularly higher, and that of COL4A4, COL6A5 and COL14A1 was especially lower in tumor tissues, indicating their possible roles as diagnostic markers for ESCC.
	0.94	COL1A1, COL11A1, COL6A6 and COL19A1, were co-expressed with NETO1, NEUROD2 and NRG3, which are the genes involved in neural functions.
	0.92	COL1A1, COL10A1 and COL11A1 in TCGA and GEO. (J-O) Boxplots of three representative down-regulated genes, COL4A4, COL6A5 and COL14A1 in TCGA and GEO.
	0.65	COL1A1, COL10A1 and COL11A1 were notably overexpressed in ESCC compared to normal tissues.
	0.64	COL1A1, COL10A1 and COL11A1 ranked in the top five among the up-regulated DEGs in both datasets (Figs. 1D-1I), further presented by boxplots.
30723390	0.97	COL11A1, THBS2, COL8A1, COL1A1, BGN, MMP2, PXDN, THY1, and TGFB1I1 was identified.
	0.97	COL1A1, (e) COL1A2, (f) COL11A1, (g) MMP2, (h) PXDN, and (i) THY1.
	0.97	COL11A1, THBS2, COL8A1, COL1A1, BGN, MMP2, PXDN, THY1, and TGFB1I1.
	0.93	COL1A1, COL1A2, COL11A1, MMP2, PXDN, BGN, COL5A1, COL8A1, and TGFB1I1 indicated poor prognosis of the patients(P < 0.05).
	0.93	COL1A1, COL1A2, COL11A1, MMP2, PXDN, and THY1 was related to the poor prognosis of the disease.
	0.93	COL1A1, COL1A2, COL11A1, MMP2, PXDN, BGN, COL5A1, COL8A1 associated with the tumor stage as well as tumor patients' prognosis.
	0.70	COL1A1, COL1A2, COL11A1, MMP2, PXDN, BGN, and THY1(Fig. 5).
30948703	0.97	COL1A1, COL3A1, COL1A2, COL5A2, FN1, THBS1, COL5A1, SPARC, COL18A1, and COL11A1) were identified via PPI network analysis.
	0.96	COL1A1, COL1A2, COL5A2, COL11A1, COL18A1, FN1, and SPARC - were related to the OS of GC patients.
	0.93	COL1A1, COL3A1, COL1A2, COL5A2, FN1, THBS1, COL5A1, SPARC, COL18A1, and COL11A1.
	0.89	COL1A1, COL5A1, and COL11A1, was upregulated in renal cell carcinoma compared with levels in controls.
	0.88	COL1A1, COL1A2, COL5A2, COL11A1, COL18A1, FN1, and SPARC was associated with poor OS of GC patients.
	0.64	COL1A1, COL3A1, COL1A2, COL5A2, FN1, THBS1, COL5A1, SPARC, COL18A1, and COL11A1.
27356888	0.97	COL1A1 and COL11A1 were included (Fig. 2A).
	0.94	COL1A1 and COL11A1 may be important gene signatures contributing to OA development via involvement in ECM-receptor interactions and focal adhesion.
	0.91	collagen type I alpha 1 (COL1A1), COL1A2, COL3A1, COL4A2, integrin alpha 1, COL4A1, biglycan and COL11A1.
	0.90	COL1A1 and COL11A1, were predominantly enriched in the ECM-receptor interaction and focal adhesion pathways.
	0.57	COL1A1 and COL11A1 may be important gene signatures in OA development via involvement in the pathways of ECM-receptor interactions and focal adhesions.
25860484	0.97	COL1A1, COL1A2, COL5A2, COL11A1, and SPP1) were most significantly altered and were all involved in the ECM-receptor interaction and focal adhesion pathway (Table 2).
	0.96	COL1A1, COL1A2, COL5A2, and COL11A1 belong to the collagen protein family, essential structural components of ECM.
	0.93	COL1A1, COL1A2, COL5A2, COL11A1, DSG3, ACHE, SERPINE1, SERPINB2, CXCL5, MMP1, PLAU, SPP1, GJB2, CLDN2, CDKN2A, CENPF, MAD2L1, and NCAM1), most of which (17 out of 18) were up-regulated in gastric cancer tissues (Fig 4).
	0.90	COL1A1, COL1A2, COL5A2, COL11A1, and SPP1) co-regulated by both TFs and miRNAs participated in ECM-receptor interaction and focal adhesion pathways.
30237810	0.97	COL1A1, COL5A1, COL5A2, COL10A1 and COL11A1, were also responsible for encoding collagens, which are the most abundant proteins in the ECM.
	0.97	COL1A1, COL5A1, COL5A2, COL10A1 and COL11A1.
	0.57	COL1A1, COL5A1, COL5A2, and COL11A1), integrin (ITGA6), tenascin (TNXB) and fibronectin (FN1).
19388929	0.97	COL11A1, COL1A1, CD44, SELE, LAMA3 and ITGA9 were significantly downregulated by PT-100 in cocultured osteoclasts.
	0.95	COL11A1, COL1A1, COLA4A2), laminins (LAMA3, LAMB1) and other adhesion molecules including E-selectin (SELE), CD44 and ITGA9.
27843486	0.97	COL1A1, COL5A1, and COL10A1, and 8 genes with degree of node 3 are FBN1, LUM, LRRC15, COL11A1, THBS2, SPARC, COL1A2, and FAP, respectively.
	0.93	COL1A1, COL5A1, and COL11A1.
28586059	0.96	COL1A1, COL11A1 and COL5A2) and neuroactive ligand-receptor interaction (dM3; P=9.49x10-4; Table IVB).
	0.94	COL1A1, COL1A2, COL3A1, COL5A2, COL6A1, COL6A2, COL6A3, COL11A1, COL12A1 and ITGA4 may interact with each other.
	0.88	COL1A1, COL11A1 and COL5A2), G-protein coupled receptor protein signaling pathway (dM3; P=7.27x10-4) and wound healing (dM4; P=1.56 x10-4; Table IVA).
22208948	0.96	COL11A1, THBS2, COL5A2, COL5A1, VCAN, COL1A1, COL3A1, FN1,SULF1, FBN1, ASPN, SPARC, CTSK, MMP2, BGN, LUM, LOXL2, COL6A3, TIMP3, CDH11, SERPINF1, EDNRA, ACTA2, PDGFRB, SNAI2, LGALS1, GLT8D2, NID2, PRRX1) belong to the set of 64 genes in Table 1 (P = 10-27), as well as VIM (vimentin).
28856171	0.96	COL1A1, COL2A1, COL11A1, COL11A2, COL12A1, COL14A1) did not have a significant independent association with tendon injury, even though they have been linked to other musculoskeletal injuries (eg, COL1A1 Sp1 with ACL tears, shoulder dislocations, osteogenesis imperfecta, and lumbar disc disease; COL2A1 with spondyloepiphyseal dysplasia).
28881680	0.96	COL11A1 and COL1A1 belong to fibrillar collagen.
28331057	0.95	Col11a1 and Col8a2, while Col1a1 transcript was ranked 7th (Fig. 1B).
	0.93	COL11A1 and COL1A1 levels were significantly increased by TGFbeta2 treatment (Fig. 5B).
	0.90	COL11A1 appeared to have very little colocalization with COL1A1.
	0.84	COL11A1 and COL1A1 in the fibrotic phase of conjunctival wound healing
	0.83	COL1A1 and low COL8A1/high COL1A1 co-immunolabellings, respectively; inset (ii) left, second image, shows a magnified image of the boxed area co-immunolabelled for COL8A1 and COL11A1; inset (ii) right, second image, shows a magnified image of the boxed area co-immunolabelled for COL11A1 and COL1A1; inset (ii), fourth image, shows a magnified overlay image of the boxed area co-immunolabelled for all three collagens.
	0.77	COL11A1 and COL1A1 in human fibroblasts treated as indicated for 72 h. Three independent sets of experiments are shown.
	0.71	COL11A1 (green) and COL1A1 (magenta).
30542454	0.95	COL1A1, COL1A2, CTSK, ITGB4, TIMP1, ITGA11, COL11A1, MYBL2, KPNA2, AURKA, TPX2 and CDC20.
	0.94	COL1A1, (D) CDC20, (E) MYBL2, (F) POSTN, (G) COL11A1, (H) TPX2, (I) COL3A1, (J) TIMP1, (K) DNALI1, (L) DNAH6, (M) CTSK, (N) DYNC2H1, (O) DNAH12 and (P) WDR78, on the survival of lung cancer patients.
	0.91	COL1A1, COL1A2, CTSK, ITGB4, TIMP1, ITGA11, COL11A1, MYBL2, KPNA2, AURKA, TPX2 and CDC20) were identified as hub genes in smoking-associated lung cancer.
	0.63	COL1A1, COL1A2, cathepsin K (CTSK), integrin subunit beta 4 (ITGB4), tissue inhibitor of metalloproteinases 1 (TIMP1), ITGA11, COL11A1, MYB proto-oncogene like 2 (MYBL2), karyopherin subunit alpha 2 (KPNA2), aurora kinase A (AURKA), TPX2, microtubule nucleation factor (TPX2) and cell division cycle 20 (CDC20) were identified as key upregulated genes in smoking-associated lung cancer (Fig. 2A and B).
29196464	0.95	COL11A1, COMP, VCAN, FN1, COL1A1 and CTSB have all been associated with cancer progression, poor prognosis and malignant cell invasion in ovarian and/or other cancers.
29360819	0.94	Col1a1 and Col11a1 in colon cancers and matched normal colon with quantification of the area (%) of the microarray core demonstrating positive staining (n=20 per analysis).
30828485	0.94	COL1A1, COL1A2, COL2A1, COL3A1, COL5A1, COL5A2, COL6A1, COL8A1, COL11A1, and COL24A1.
26870242	0.93	COL1A1, COL5A2, THBS2, COL11A1 and COL5A1) were involved in the ECM-receptor interaction pathway.
	0.78	COL1A1, COL5A2, thrombospondin 2 (THBS2), COL11A1 and COL5A1] were predicted to participate in the pathway.
31427586	0.93	COL1A1 variants (3/5), 100% for spondyloepiphyseal dysplasia congenita with a COL2A1 variant (1/1), 100% for Stickler syndrome with COL11A1, COL11A2 variants (2/3, 1/3), 33% for CHARGE syndrome with a CHD7 variant (1/3), 100% for Jervell and Lange-Nielsen syndrome with a KCNQ1 variant (1/1), 100% for auditory neuropathy with a OPA1 mutation (1/1), and 89% for Pendred syndrome with SLC26A4 variants (32/36).
29601813	0.92	COL1A1 expression was highest by ~2-3 orders of magnitude when compared to COL11A1 and by ~6 orders of magnitude when compared to COL3A1.
	0.85	COL1A1, COL3A1, and COL11A1 were not affected by peptide motif, fiber stiffness, or loading.
19652764	0.92	COL11A1, COL1A1, COL3A1, COL1A2, COL15A1).
29358879	0.91	COL11A1, BMP7, MMP12, LAMC2, COL27A1, ITGB4, PDGFRA, ADAMTS2, IBSP, COL10A1, COL7A1, MMP11, MFAP2, MMP1, and COL1A1.
	0.83	COL11A1, BMP7, MMP12, LAMC2, COL27A1, ITGB4, PDGFRA, ADAMTS2, IBSP, COL10A1, COL7A1, MMP11, MFAP2, MMP1, and COL1A1.
30572540	0.91	COL1A1, COL10A1, COL11A1, CCL20, and CXCL5, could be used not only for the differential diagnosis of PTC from normal samples, but also for the differential diagnosis of TCPTC from cPTC samples.
23936839	0.90	collagen type I, alpha 1 (COL1A1; 1.62-fold change), collagen type XI, alpha 1 (COL11A1; 1.82-fold change), and collagen type XIV, alpha 1 (COL14A1; 2.06-fold change), was upregulated by PC.
20952505	0.89	COL11A1, COL1A1, COL3A1, CALD1, and TNNC1).
27626164	0.88	COL1A1 and COL11A1 were also behaved up-regulation trend in cancer, except FLNC.
	0.55	COL1A1 and COL11A1 in tumor tissues were obviously higher than non-tumor tissues (Figure S3B-S3D), which illustrates that tumor invasion and metastasis related pathways were up-regulated in tumor compared with non-tumor tissues, especially for FLNC.These results further demonstrated that the up-regulation of FLNC is a common phenomenon in HCC and FLNC might have the potential to be used as a biomarker for HCC diagnosis.
29844680	0.88	COL11A1, COL4A1, COL5A2, COL5A1, COL1A1, COL1A2, COL5A3 and THBS2) and 46 edges with a score of 8.5 was detected by MCODE.
22550553	0.87	COL1A1, COL9A1, COL9A2, COL9A3, COL11A1, COL11A2), vitamin D receptor (VDR), matrix metalloproteinases (MMP2, MMP3, MMP9), interleukins (IL1, IL2, IL18R1, IL18RAP), cyclooxygenase-2 (COX2) and cartilage intermediate layer protein (CILP) have been reported with different pathologic changes of disc degeneration and clinical phenotypes.
32058995	0.87	COL1A1, COL11A1, COL4A6, and THBS2) are involved in both pathways.
23372777	0.83	COL1A1, COL1A2 and COL3A1, other collagens (COL4-6A2 and COL12A1), and ECM genes (BGN, VCAN, DCN, SPARC, SPON1 and THBS1) were up-regulated in PanIN-X lesions and PDACs; in PDACs, stromal involvement was characterised by an even higher diversity of collagens (COL10A1, COL11A1, COL14-16A1 and COL18A1 were additionally seen), and even higher expression than in PanIN-X lesions of the ECM genes mentioned above.
23555081	0.77	COL1A1; 1.66-fold change), and collagen type XI alpha-1 (COL11A1; 1.50-fold change), was upregulated by PC (Table 2).
26351771	0.50	collagen type I alpha 1 (COL1A1); COL5A1; COL11A1; COL14A1; COL16A1; contactin 1; connective tissue growth factor (CTGF); catenin, alpha 1; catenin Delta 2; integrin beta 2 (ITGB2); kallmann syndrome 1 sequence (KAL1); laminin alpha 3 (LAMA3); matrix metallopeptidase 2 (MMP2); MMP3; MMP7; MMP12; MMP13; selectin E; secreted protein acidic, cysteine-rich (SPARC); transforming growth factor, beta-induced; Thrombospondin 3 (THBS3); and Versican (VCAN).